Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II--tissue distribution.
Tobramycin-loaded solid lipid nanoparticles (SLN) were prepared and administered by duodenal and intravenous (i.v.) routes to rats and the tissue distributions were determined successively at fixed times (30 min, 4 h and 24 h) and compared to those of the tobramycin solution after i.v. administration. The tissue distribution between tobramycin-loaded SLN administered duodenally and i.v. was different. A marked difference between tobramycin-loaded SLN administered duodenally and tobramycin solution administered i.v. was also evidenced. In particular, the amounts of tobramycin in the kidneys after tobramycin-loaded SLN administration either duodenally or i.v. were lower than after administration of i.v. solution. Tobramycin-loaded SLN were able to pass across the blood-brain barrier in rats to a greater extent after i.v. injection than after duodenal administration.
Bargoni
A
A
Dipartimento di Fisiopatologia Clinica-Università degli Studi di Torino, Italy
Cavalli
R
R
Zara
G P
GP
Fundarò
A
A
Caputo
O
O
Gasco
M R
MR
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004337:Drug Carriers; D004386:Duodenum / Q000502:physiology*; D007267:Injections; D007275:Injections, Intravenous; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism*; D008081:Liposomes; D008297:Male; D019999:Pharmaceutical Solutions; D051381:Rats; D017208:Rats, Wistar; D014018:Tissue Distribution; D014031:Tobramycin / Q000008:administration & dosage / Q000493:pharmacokinetics*
D000900:Anti-Bacterial Agents; D004337:Drug Carriers; D008081:Liposomes; D019999:Pharmaceutical Solutions; D014031:Tobramycin